A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer’s

References

• Breijyeh Z, Karaman R. Comprehensive review on alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789. doi:10.3390/molecules25245789.
   PubMed Web of Science ®Google Scholar
• Dementia [Internet]. 2023. https://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• Vogt A-CS, Jennings GT, Mohsen MO, et al. Alzheimer’s disease: a brief history of immunotherapies targeting amyloid β. Int J Mol Sci. 2023;24:3895. doi:10.3390/ijms24043895.
   PubMed Web of Science ®Google Scholar
• Marcuzzi A. Alzheimer’s disease epidemic in Europe. 2020.
   Google Scholar
• Lee J, Meijer E, Langa KM, et al. Prevalence of dementia in India: national and state estimates from a nationwide study. Alzheimer’s Dement. 2023. doi:10.1002/alz.12928
   Web of Science ®Google Scholar
• Gaugler J, James B, Johnson T, et al. Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18:700–789.
   PubMed Web of Science ®Google Scholar
• Revi M. Alzheimer’s disease therapeutic approaches. Adv Exp Med Biol. 2020;1195:105–116.
   PubMed Web of Science ®Google Scholar
• Kumar A, Chaudhary RK, Singh R, et al. Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front Neurosci. 2020;14:305. doi:10.3389/fnins.2020.00305.
   PubMed Web of Science ®Google Scholar
• Padmanabhan P, Palanivel M, Kumar A, et al. Nanotheranostic agents for neurodegenerative diseases. Emerg Top Life Sci. 2020;4(6):645–675. doi:10.1042/ETLS20190141.
   PubMedGoogle Scholar
• Singh R, Deshmukh R. Carbon nanotube as an emerging theranostic tool for oncology. J Drug Deliv Sci Technol. 2022;74:103586. doi:10.1016/j.jddst.2022.103586.
   Web of Science ®Google Scholar
• Rastogi V, Yadav P, Bhattacharya SS, et al. Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Delivery. 2014;2014:670815. doi:10.1155/2014/670815.
   PubMedGoogle Scholar
• Rizwanullah M, Ahmad MZ, Garg A, et al. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochim Biophys Acta Gen Subj. 2021;1865(9):129936. doi:10.1016/j.bbagen.2021.129936.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Leong DT, Mei L, et al. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theran Ivyspring Inter Publis. 2014;4(6):660–677. doi:10.7150/thno.8698.
   Google Scholar
• Carro CE, Pilozzi AR, Huang X. Nanoneurotoxicity and potential nanotheranostics for alzheimer’s disease. EC Pharmacol Toxicol. 2019;7(12):1–7.
   PubMedGoogle Scholar
• Mufson EJ, Mahady L, Waters D, et al. Hippocampal plasticity during the progression of Alzheimer’s disease HHS public access. Neuroscience. 2015;309:51–67.
   Google Scholar
• Vyas Y, Montgomery JM, Cheyne JE. Hippocampal deficits in amyloid-β-Related rodent models of alzheimer’s disease. Front Neurosci. 2020;14:266. doi:10.3389/fnins.2020.00266.
   PubMed Web of Science ®Google Scholar
• Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205–1235. doi:10.1038/aps.2017.28.
   PubMed Web of Science ®Google Scholar
• Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008;35(12):2169–2181. doi:10.1007/s00259-008-0833-y.
   PubMed Web of Science ®Google Scholar
• Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical alzheimer’s disease. Neuroimage Clin. 2013;2:356–365. doi:10.1016/j.nicl.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Gella A, Durany N. Oxidative stress in alzheimer disease. Cell Adh Migr. 2009;3(1):88–93. doi:10.4161/cam.3.1.7402.
   PubMed Web of Science ®Google Scholar
• Rose VL. Alzheimer’s disease genetic fact sheet. Am Fam Physician. 1998;58:578.
   Google Scholar
• Atri A. Current and future treatments in alzheimer’s disease. Semin Neurol. 2019;39(2):227–240. Thieme Medical Publishers doi:10.1055/s-0039-1678581.
   PubMed Web of Science ®Google Scholar
• Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397. doi:10.1177/1179573520907397.
   Web of Science ®Google Scholar
• Frozza RL, Lourenco MV, De Felice FG. Challenges for Alzheimer’s disease therapy: insights from novel mechanisms beyond memory defects. Front Neurosci. 2018;12:37. doi:10.3389/fnins.2018.00037.
   PubMed Web of Science ®Google Scholar
• Cunha S, Forbes B, Lobo JMS, et al. Improving drug delivery for alzheimer’s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int J Nanomedicine. 2021;16:4373–4390. doi:10.2147/IJN.S305851.
   PubMed Web of Science ®Google Scholar
• Cai Z, Qiao PF, Wan CQ, et al. Role of Blood-Brain barrier in Alzheimer’s disease. J Alzheimers Dis. 2018;63(4):1223–1234. doi:10.3233/JAD-180098.
   PubMed Web of Science ®Google Scholar
• Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis. 2017;107:41–56. doi:10.1016/j.nbd.2016.07.007.
   PubMed Web of Science ®Google Scholar
• Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab. 2013;33(10):1500–1513. doi:10.1038/jcbfm.2013.135.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Nguyen TD, Nguyen TKO, et al. Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed Pharmacother. 2021;139:111623.
   Google Scholar
• Tsuji A. Small molecular drug transfer across the Blood-Brain barrier via Carrier-Mediated transport systems. NeuroRx. 2005;2(1):54–62. doi:10.1602/neurorx.2.1.54.
   PubMedGoogle Scholar
• Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites . Curr Pharm Des. 2014;20(10):1422–1449. doi:10.2174/13816128113199990463.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xi Z, Zinman L, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain. 2015;138(Pt 9):e380. doi:10.1093/brain/awv082.
   PubMedGoogle Scholar
• Dilnawaz F, Singh A, Mewar S, et al. The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials [Internet]. 2012;33Jul 4cited(10):2936–2951. doi:10.1016/j.biomaterials.2011.12.046.
   PubMed Web of Science ®Google Scholar
• Ruff J, Hüwel S, Kogan MJ, et al. The effects of gold nanoparticles functionalized with ß-amyloid specific peptides on an in vitro model of blood–brain barrier. Nanomedicine. 2017;13(5):1645–1652. doi:10.1016/j.nano.2017.02.013.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Rehman SU, Amin FU, et al. Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aβ1-42-induced neuroinflammation and neurodegeneration via the NF-KB/JNK/GSK3β signaling pathway. Nanomedicine. 2017;13(8):2533–2544. doi:10.1016/j.nano.2017.06.022.
   PubMed Web of Science ®Google Scholar
• Tak K, Sharma R, Dave V, et al. Clitoria ternatea mediated synthesis of graphene quantum dots for the treatment of alzheimer’s disease. ACS Chem Neurosci. 2020;11(22):3741–3748. doi:10.1021/acschemneuro.0c00273.
   PubMed Web of Science ®Google Scholar
• Liu H, Dong X, Liu F, et al. Iminodiacetic acid-conjugated nanoparticles as a bifunctional modulator against Zn2+-mediated amyloid β-protein aggregation and cytotoxicity. J Colloid Interface Sci. 2017;505:973–982. doi:10.1016/j.jcis.2017.06.093.
   PubMed Web of Science ®Google Scholar
• Mirsadeghi S, Shanehsazzadeh S, Atyabi F, et al. Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid beta fibrillation process. Mater Sci Eng C Mater Biol Appl. 2016;59:390–397. doi:10.1016/j.msec.2015.10.026.
   PubMed Web of Science ®Google Scholar
• Yang L, Yin T, Liu Y, et al. Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for alzheimer’s disease treatment. Acta Biomater. 2016;46:177–190. doi:10.1016/j.actbio.2016.09.010.
   PubMed Web of Science ®Google Scholar
• Liao YH, Chang YJ, Yoshiike Y, et al. Negatively charged gold nanoparticles inhibit alzheimer’s amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small. 2012;8(23):3631–3639. doi:10.1002/smll.201201068.
   PubMed Web of Science ®Google Scholar
• Hu B, Dai F, Fan Z, et al. Nanotheranostics: Congo red/Rutin-MNPs with enhanced magnetic resonance imaging and H2O2-Responsive therapy of alzheimer’s disease in APPswe/PS1dE9 transgenic mice. Adv Mater. 2015;27(37):5499–5505. doi:10.1002/adma.201502227.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cha MY, Kim D, et al. Mitochondria-Targeting ceria nanoparticles as antioxidants for alzheimeŕs disease. ACS Nano. 2016;10(2):2860–2870. doi:10.1021/acsnano.5b08045.
   PubMed Web of Science ®Google Scholar
• Mars A, Hamami M, Bechnak L, et al. Curcumin-graphene quantum dots for dual mode sensing platform: electrochemical and fluorescence detection of APOe4, responsible of alzheimer’s disease. Anal Chim Acta. 2018;1036:141–146. doi:10.1016/j.aca.2018.06.075.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhang L, Zhao J, et al. Advances in aptamers against Aβ and applications in Aβ detection and regulation for alzheimer’s disease. Theranostics. 2022;12(5):2095–2114. doi:10.7150/thno.69465.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Figueroa-Miranda G, Wu C, et al. Electrochemical dual-aptamer biosensors based on nanostructured multielectrode arrays for the detection of neuronal biomarkers. Nanoscale. 2020;12(31):16501–16513. doi:10.1039/d0nr03421e.
   PubMed Web of Science ®Google Scholar
• Oyarzún MP, Tapia-Arellano A, Cabrera P, et al. Plasmonic nanoparticles as optical sensing probes for the detection of alzheimer’s disease. Sensors. 2021;21:2022–2030. doi:10.3390/s21062067.
   PubMed Web of Science ®Google Scholar
• Kim K, Kim M-J, Won Kim D, et al. Clinically accurate diagnosis of alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma. Nature Communicat. 11(1):119.
   PubMed Web of Science ®Google Scholar
• Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011; 23(36):H217–47. doi:10.1002/adma.201102313.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim J, Bark CW, et al. Spotlight on nano-theranostics in South Korea: applications in diagnostics and treatment of diseases. Int J Nanomedicine. 2015;10(Spec Iss):3–8. doi:10.2147/IJN.S91389.
   PubMedGoogle Scholar
• Mir Najib Ullah SN, Afzal O, Altamimi ASA, et al. Nanomedicine in the management of alzheimer’s disease: state-of-the-Art. Biomedicines. 2023;11:1752. doi:10.3390/biomedicines11061752.
   PubMed Web of Science ®Google Scholar
• Alyautdin R, Khalin I, Nafeeza MI, et al. Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomedicine. 2014;9:795–811. doi:10.2147/IJN.S52236.
   PubMed Web of Science ®Google Scholar
• Mudshinge SR, Deore AB, Patil S, et al. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J. 2011;19(3):129–141. doi:10.1016/j.jsps.2011.04.001.
   PubMed Web of Science ®Google Scholar
• Tao X, Mao S, Zhang Q, et al. Brain-targeted polysorbate 80-emulsified donepezil drug-loaded nanoparticles for neuroprotection. Nanoscale Res Lett. 2021;16(1):132. doi:10.1186/s11671-021-03584-1.
   PubMed Web of Science ®Google Scholar
• Sánchez-López E, Ettcheto M, Egea MA, et al. Memantine loaded PLGA PEGylated nanoparticles for alzheimer’s disease: in vitro and in vivo characterization. J Nanobiotechnology. 2018;16(1):32. doi:10.1186/s12951-018-0356-z.
   PubMedGoogle Scholar
• Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology based theranostic approaches in alzheimer’s disease management: Current status and future perspective. Curr Alzheimer Res. 2017;14(11):1164–1181. doi:10.2174/1567205014666170508121031.
   PubMed Web of Science ®Google Scholar
• Barage SH, Sonawane KD. Amyloid Cascade hypothesis: Pathogenesis and therapeutic strategies in alzheimer’s disease. Neuropeptides. 2015;52:1–18. doi:10.1016/j.npep.2015.06.008.
   PubMed Web of Science ®Google Scholar
• Javed I, He J, Kakinen A, et al. Probing the aggregation and immune response of human islet amyloid polypeptides with Ligand-Stabilized gold nanoparticles. ACS Appl Mater Interfaces. 2019;11(11):10462–10471. doi:10.1021/acsami.8b19506.
   PubMed Web of Science ®Google Scholar
• Gladytz A, Abel B, Risselada HJ. Gold-Induced fibril growth: the mechanism of Surface-Facilitated amyloid aggregation. Angew Chem Int Ed Engl. 2016;55(37):11242–11246. doi:10.1002/anie.201605151.
   PubMed Web of Science ®Google Scholar
• Canovi M, Markoutsa E, Lazar AN, et al. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials. 2011;32(23):5489–5497. doi:10.1016/j.biomaterials.2011.04.020.
   PubMed Web of Science ®Google Scholar
• Nazem A, Mansoori GA. Nanotechnology for alzheimer’s disease detection and treatment. Insciences J. 2011;1(4):169–193. doi:10.5640/insc.0104169.
   Google Scholar
• Sharma B, Pervushin K. Magnetic nanoparticles as in vivo tracers for alzheimer’s disease. Magnetochemistry. 2020;6(1):13. doi:10.3390/magnetochemistry6010013.
   Web of Science ®Google Scholar
• Sharma M, Dube T, Chibh S, et al. Nanotheranostics, a future remedy of neurological disorders. Expert Opin Drug Deliv. 2019;16(2):113–128. doi:10.1080/17425247.2019.1562443.
   PubMed Web of Science ®Google Scholar
• Aulić S, Bolognesi ML, Legname G. Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol. 2013;2013:150952. doi:10.1155/2013/150952.
   PubMedGoogle Scholar
• Bhanderi M, Shah J, Gorain B, et al. Optimized rivastigmine nanoparticles coated with eudragit for intranasal application to brain delivery: evaluation and nasal ciliotoxicity studies. Materials (Basel). 2021;14:6291. doi:10.3390/ma14216291.
   PubMed Web of Science ®Google Scholar
• Silva S, Marto J, Gonçalves L, et al. Formulation, characterization and evaluation against SH-SY5Y cells of new tacrine and tacrine-MAP loaded with lipid nanoparticles. Nanomaterials. 2020;10(10):2089. doi:10.3390/nano10102089.
   Web of Science ®Google Scholar
• Arbez-Gindre C, Steele BR, Micha-Screttas M. Dendrimers in alzheimer’s disease: recent approaches in Multi-Targeting strategies. Pharmaceutics. 2023;15:898. doi:10.3390/pharmaceutics15030898.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Pang Z. Dendrimer-based drug delivery systems for brain targeting. Biomolecules. 2019;9:790. doi:10.3390/biom9120790.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu L-P, Dai W, et al. Graphene quantum dots for the inhibition of β amyloid aggregation. Nanoscale. 2015;7(45):19060–19065. doi:10.1039/c5nr06282a.
   PubMed Web of Science ®Google Scholar
• Hasannejadasl B, Janbaz FP, Choupani E, et al. Quantum dots application in neurodegenerative diseases. Thrita. 2021;9(2):e100105. doi:10.5812/thrita.100105.
   Google Scholar
• Li X, Yang Y, Zhao H, et al. Enhanced in vivo blood–brain barrier penetration by circular tau–transferrin receptor bifunctional aptamer for tauopathy therapy. J Am Chem Soc. 2020;142(8):3862–3872. doi:10.1021/jacs.9b11490.
   PubMed Web of Science ®Google Scholar
• Ruan Y, Xiong Y, Fang W, et al. Highly sensitive curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of alzheimer’s disease via NLRP3-inhibition. J Nanobiotechnology. 2022; 20(1):322. doi:10.1186/s12951-022-01524-4.
   PubMed Web of Science ®Google Scholar
• Van Giau V, An SSA, Hulme JP. Mitochondrial therapeutic interventions in alzheimer’s disease. J Neurol Sci. 2018; 395:62–70. doi:10.1016/j.jns.2018.09.033.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Lanzillotta C, Perluigi M, et al. Oxidative stress, protein modification and alzheimer disease. Brain Res Bull. 2017;133:88–96. doi:10.1016/j.brainresbull.2016.06.005.
   PubMed Web of Science ®Google Scholar
• Hauptmann S, Scherping I, Dröse S, et al. Mitochondrial dysfunction: an early event in alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30(10):1574–1586. doi:10.1016/j.neurobiolaging.2007.12.005.
   PubMed Web of Science ®Google Scholar
• Du H, Guo L, Yan S, et al. Early deficits in synaptic mitochondria in an alzheimer’s disease mouse model. Proc Natl Acad Sci U S A. 2010;107(43):18670–18675. doi:10.1073/pnas.1006586107.
   PubMed Web of Science ®Google Scholar
• Harwansh RK, Bahadur S, Deshmukh R, et al. Exciting potential of nanoparticlized lipidic system for effective treatment of breast cancer and clinical updates: a translational prospective. Curr Pharm Des. 2020;26(11):1191–1205. doi:10.2174/1381612826666200131101156.
   PubMed Web of Science ®Google Scholar
• Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064–1079. doi:10.1016/j.addr.2010.07.009.
   PubMed Web of Science ®Google Scholar
• Huo X, Zhang Y, Jin X, et al. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in alzheimer’s disease. J Photochem Photobiol B. 2019;190:98–102. doi:10.1016/j.jphotobiol.2018.11.008.
   PubMed Web of Science ®Google Scholar
• Hou K, Zhao J, Wang H, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of alzheimer’s disease. Nat Commun. 2020;11(1):4790. doi:10.1038/s41467-020-18525-2.
   PubMed Web of Science ®Google Scholar
• Khan NH, Mir M, Ngowi EE, et al. Nanomedicine: a promising way to manage alzheimer’s disease. Front Bioeng Biotechnol. 2021;9:630055. doi:10.3389/fbioe.2021.630055.
   PubMed Web of Science ®Google Scholar
• Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A. 2012;109(40):16288–16293. doi:10.1073/pnas.1210096109.
   PubMed Web of Science ®Google Scholar
• Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in alzheimer’s disease model via canonical wnt/β-catenin pathway. ACS Nano. 2014;8(1):76–103. doi:10.1021/nn405077y.
   PubMed Web of Science ®Google Scholar
• Wang ZH, Wang ZY, Sun CS, et al. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010;31(5):908–915. doi:10.1016/j.biomaterials.2009.09.104.
   PubMed Web of Science ®Google Scholar
• Luo Q, Lin YX, Yang PP, et al. A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat Commun. 2018;9(1):1802. doi:10.1038/s41467-018-04255-z.
   PubMedGoogle Scholar
• Carradori D, Balducci C, Re F, et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in alzheimer’s disease-like transgenic mouse model. Nanomedicine. 2018;14(2):609–618. doi:10.1016/j.nano.2017.12.006.
   PubMed Web of Science ®Google Scholar
• Vilella A, Belletti D, Sauer AK, et al. Reduced plaque size and inflammation in the APP23 mouse model for alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J Trace Elem Med Biol. 2018;49:210–221. doi:10.1016/j.jtemb.2017.12.006.
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. Intranasal delivery of huperzine a to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of alzheimer’s disease. Int J Nanomedicine. 2018;13:705–718. doi:10.2147/IJN.S151474.
   PubMed Web of Science ®Google Scholar
• Joseph A, Wood T, Chen CC, et al. Curcumin-loaded polymeric nanoparticles for neuroprotection in neonatal rats with hypoxic-ischemic encephalopathy. Nano Res. 2018;11(10):5670–5688. doi:10.1007/s12274-018-2104-y.
   Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449. doi:10.1172/JCI18162.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Dhommati R, Jain A, et al. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for alzheimer’s disease. Eur J Pharm Sci. 2016;92:224–234. doi:10.1016/j.ejps.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Pinheiro RGR, Granja A, Loureiro JA, et al. RVG29-Functionalized lipid nanoparticles for quercetin brain delivery and alzheimer’s disease. Pharm Res. 2020;37(7):139. doi:10.1007/s11095-020-02865-1.
   PubMed Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301. doi:10.1016/j.colsurfb.2017.01.031.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of alzheimer’s disease mice. Biomaterials. 2014;35(1):456–465. doi:10.1016/j.biomaterials.2013.09.063.
   PubMed Web of Science ®Google Scholar
• Skaat H, Corem-Slakmon E, Grinberg I, et al. Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils. Int J Nanomedicine. 2013;8:4063–4076. doi:10.2147/IJN.S52833.
   PubMed Web of Science ®Google Scholar
• Agyare EK, Jaruszewski KM, Curran GL, et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014;185:121–129. doi:10.1016/j.jconrel.2014.04.010.
   PubMed Web of Science ®Google Scholar
• Jaruszewski KM, Curran GL, Swaminathan SK, et al. Multimodal nanoprobes to target cerebrovascular amyloid in alzheimer’s disease brain. Biomaterials. 2014;35(6):1967–1976. doi:10.1016/j.biomaterials.2013.10.075.
   PubMed Web of Science ®Google Scholar
• Dehvari K, Lin K-S. Synthesis, characterization and potential applications of multifunctional PEO-PPOPEO-magnetic drug delivery system. Curr Med Chem. 2012;19(30):5199–5204. doi:10.2174/092986712803530584.
   PubMed Web of Science ®Google Scholar
• Choi J, Choi HJ, Jung DC, et al. Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid β self-assembly. Chem Commun. 2008;(19):2197–2199. doi:10.1039/b803294g.
   PubMed Web of Science ®Google Scholar
• Tokuraku K, Marquardt M, Ikezu T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS One [Internet]. 2009; 4(12):e8492. doi:10.1371/journal.pone.0008492.
   PubMed Web of Science ®Google Scholar
• Zhang D, Fa H-B, Zhou J-T, et al. The detection of β-amyloid plaques in an alzheimer’s disease rat model with DDNP-SPIO. Clin Radiol. 2015;70(1):74–80. doi:10.1016/j.crad.2014.09.019.
   PubMed Web of Science ®Google Scholar
• Sillerud LO, Solberg NO, Chamberlain R, et al. SPION-enhanced magnetic resonance imaging of alzheimer’s disease plaques in AβPP/PS-1 transgenic mouse brain. J Alzheimers Dis. 2013;34(2):349–365. doi:10.3233/JAD-121171.
   PubMed Web of Science ®Google Scholar
• Rastogi V, Yadav P, Porwal M, et al. Dendrimer as nanocarrier for drug delivery and drug targeting therapeutics: a fundamental to advanced systematic review. Inter J Polymeric Mater Polymeric Biomater. 2022; doi:10.1080/00914037.2022.2158334.
   Web of Science ®Google Scholar
• Stiriba SE, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed Engl. 2002;41(8):1329–1334. doi:10.1002/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Al-Azzawi S, Masheta D, Guildford AL, et al. Dendrimeric poly(Epsilon-Lysine) delivery systems for the enhanced permeability of flurbiprofen across the Blood-Brain barrier in Alzheimer’s disease. Int J Mol Sci. 2018;19(10):3224. doi:10.3390/ijms19103224.
   PubMed Web of Science ®Google Scholar
• Aso E, Martinsson I, Appelhans D, et al. Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine. 2019;17:198–209. doi:10.1016/j.nano.2019.01.010.
   PubMed Web of Science ®Google Scholar
• Wasiak T, Ionov M, Nieznanski K, et al. Phosphorus dendrimers affect alzheimer’s (Aβ1-28) peptide and MAP-Tau protein aggregation. Mol Pharm. 2012;9(3):458–469. doi:10.1021/mp2005627.
   PubMedGoogle Scholar
• Ray S, Li Z, Hsu CH, et al. Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics. Theranostics. 2018;8(22):6322–6349. doi:10.7150/thno.27828.
   PubMed Web of Science ®Google Scholar
• Devedžić A, University of Sarajevo Bosnia and Herzegovina. Beauty of fine Dots-Detection and treatment of alzheimer’s disease using CdSe/ZnS quantum dots. NTMB. 2017;4(2):1–5. doi:10.24966/NTMB-2044/100016.
   Google Scholar
• Xiao S, Zhou D, Luan P, et al. Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability. Biomaterials. 2016;106:98–110. doi:10.1016/j.biomaterials.2016.08.021.
   PubMed Web of Science ®Google Scholar
• Guo X, Lie Q, Liu Y, et al. Multifunctional selenium quantum dots for the treatment of alzheimer’s disease by reducing Aβ-Neurotoxicity and oxidative stress and alleviate neuroinflammation. ACS Appl Mater Interfaces. 2021;13(26):30261–30273. doi:10.1021/acsami.1c00690.
   PubMed Web of Science ®Google Scholar
• Tang M, Pi J, Long Y, et al. Quantum dots-based sandwich immunoassay for sensitive detection of alzheimer’s disease-related Aβ 1-42. Spectrochim Acta A Mol Biomol Spectrosc. 2018; 201:82–87. doi:10.1016/j.saa.2018.04.060.
   PubMed Web of Science ®Google Scholar
• Pi J, Long Y, Huang N, et al. A sandwich immunoassay for detection of Aβ1-42 based on quantum dots. Talanta. 2016;146:10–15. doi:10.1016/j.talanta.2015.08.022.
   PubMed Web of Science ®Google Scholar
• Medina-Sánchez M, Miserere S, Morales-Narváez E, et al. On-chip magneto-immunoassay for alzheimer’s biomarker electrochemical detection by using quantum dots as labels. Biosens Bioelectron. 2014;54:279–284. doi:10.1016/j.bios.2013.10.069.
   PubMed Web of Science ®Google Scholar
• Ho YP, Leong KW. Quantum dot-based theranostics. Nanoscale [Internet]. 2010;2(1):60–68. doi:10.1039/b9nr00178f.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang P, Li S, et al. Development of DNA aptamer as a β-Amyloid aggregation inhibitor. ACS Appl Bio Mater. 2020;3(12):8611–8618. doi:10.1021/acsabm.0c00996.
   PubMedGoogle Scholar
• Rahimi F, Murakami K, Summers JL, et al. RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS One [Internet]. 2009; 4(11):e7694. doi:10.1371/journal.pone.0007694.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tada K, Mihara H. RNA aptamers selected against amyloid beta-peptide (abeta) inhibit the aggregation of abeta. Mol Biosyst. 2009;5(9):986–991. doi:10.1039/b903391b.
   PubMedGoogle Scholar
• Babu E, Muthu Mareeswaran P, Sathish V, et al. Sensing and inhibition of amyloid-β based on the simple luminescent aptamer-ruthenium complex system. Talanta. 2015;134:348–353. doi:10.1016/j.talanta.2014.11.020.
   PubMed Web of Science ®Google Scholar
• Li Q, Maier SH, Li P, et al. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma. Radiat Oncol. 2020;15(1):189. doi:10.1186/s13014-020-01624-1.
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373–379. doi:10.1001/archneur.58.3.373.
   PubMedGoogle Scholar
• Johnson KA, Fox NC, Sperling RA, et al. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(4):a006213. doi:10.1101/cshperspect.a006213.
   PubMed Web of Science ®Google Scholar
• Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med. 2003;50(2):293–302. doi:10.1002/mrm.10529.
   PubMed Web of Science ®Google Scholar
• Yang J, Zaim Wadghiri Y, Minh Hoang D, et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in alzheimer’s disease transgenic mice using magnetic resonance microimaging. Neuroimage [Internet]. 2011; 55(4):1600–1609. doi:10.1016/j.neuroimage.2011.01.023.
   PubMed Web of Science ®Google Scholar
• Viola KL, Sbarboro J, Sureka R, et al. Towards non-invasive diagnostic imaging of early-stage alzheimer’s disease. Nat Nanotechnol. 2015;10(1):91–98. doi:10.1038/nnano.2014.254.
   PubMed Web of Science ®Google Scholar
• Murar M, Albertazzi L, Pujals S. Advanced optical imaging-guided nanotheranostics towards personalized cancer drug delivery. Nanomaterials. 2022;12(3):399. doi:10.3390/nano12030399.
   Web of Science ®Google Scholar
• Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804(7):1405–1412. doi:10.1016/j.bbapap.2010.04.001.
   PubMed Web of Science ®Google Scholar
• Shukla R, Singh A, Handa M, et al. Nanotechnological ­approaches for targeting amyloid-β aggregation with ­potential for neurodegenerative disease therapy and diagnosis. Drug Discov Today. 2021;26(8):1972–1979. doi:10.1016/j.drudis.2021.04.011.
   PubMed Web of Science ®Google Scholar
• Nesterov EE, Skoch J, Hyman BT, et al. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl. 2005;44(34):5452–5456. doi:10.1002/anie.200500845.
   PubMed Web of Science ®Google Scholar
• Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta. 2005; 358(1-2):37–54. doi:10.1016/j.cccn.2005.03.014.
   PubMed Web of Science ®Google Scholar
• Jaiswal JK, Mattoussi H, Mauro JM, et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol. 2003;21(1):47–51. doi:10.1038/nbt767.
   PubMed Web of Science ®Google Scholar
• Akhter S, Zaki Ahmad M, Singh A, et al. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des. 2011;17(18):1834–1850. doi:10.2174/138161211796391001.
   PubMed Web of Science ®Google Scholar
• Dubertret B, Skourides P, Norris DJ, et al. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298(5599):1759–1762. doi:10.1126/science.1077194.
   PubMed Web of Science ®Google Scholar
• Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for alzheimer’s disease. Proc Natl Acad Sci U S A. 2005;102(7):2273–2276. doi:10.1073/pnas.0409336102.
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Bionanotechnologies for treatment and diagnosis of Alzheimer’s disease. Nanomedicine. 2011;7(5):515–518. doi:10.1016/j.nano.2011.05.001.
   PubMed Web of Science ®Google Scholar
• Haes AJ, Chang L, Klein WL, et al. Detection of a biomarker for Alzheimer’s disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc. 2005;127(7):2264–2271. doi:10.1021/ja044087q.
   PubMed Web of Science ®Google Scholar
• Kang DY, Lee JH, Oh BK, et al. Ultra-sensitive immunosensor for β-amyloid (1–42) using scanning tunneling microscopy-based electrical detection. Biosens Bioelectron. 2009;24(5):1431–1436. doi:10.1016/j.bios.2008.08.018.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Galván A, Contreras-Torres FF. Scanning tunneling microscopy of biological structures: an elusive goal for many years. Nanomater. 2022;12(17):3013. doi:10.3390/nano12173013.
   Web of Science ®Google Scholar
• Neely A, Perry C, Varisli B, et al. Ultrasensitive and highly selective detection of alzheimer’s disease biomarker using Two-Photon rayleigh scattering properties of gold nanoparticle. ACS Nano [Internet]. 2009;3(9):2834–2840. doi:10.1021/nn900813b.
   PubMed Web of Science ®Google Scholar
• Kim JW, Galanzha EI, Zaharoff DA, et al. Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm. 2013;10(3):813–830. doi:10.1021/mp300577s.
   PubMedGoogle Scholar
• Chhabra R, Tosi G, Grabrucker A. Emerging use of nanotechnology in the treatment of neurological disorders. Curr Pharm Des. 2015;21(22):3111–3130. doi:10.2174/1381612821666150531164124.
   PubMed Web of Science ®Google Scholar